📰 Valuating News
Page 15 - Valuating News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Valuating. Real-time updates on events, politics, business and more.
March 29, 2022
In the first public appearance since her return to China in September last year after 3 years of detention, Huaweis Chief Financial Officer (CFO) Meng Wanzhou said the company is still evaluating its response to Western sanctions on Russia.
March 28, 2022
Pivotal Phase 3 clinical trial investigates the efficacy of lead Microbiome Ecosystem Therapy MaaT013 as third-line treatment in patients with steroid-resistant gastrointestinal acute Graft-versus-Host
March 26, 2022
Use of ruxolitinib cream (Opzelura) resulted in further improvement in facial and total body repigmentation at Week 52 Results will be featured as an oral presentation in a late-breaking abstract session
March 24, 2022
Open-label basket trial will assess the safety and efficacy of Zepzelca in patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination
March 22, 2022
Study met primary endpoint, demonstrating noninferior total IgG reduction at day 29 with subcutaneously administered efgartigimod compared to intravenous (IV) administration Secondary endpoints show
March 15, 2022
- Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone - - Data support the
March 14, 2022
Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer AMEERA-3 trial did not meet primary endpoint of improving progression-free survivalOngoing
February 23, 2022
-- Teprotumumab is marketed under the brand name TEPEZZA in the United States -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical
February 23, 2022
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III
February 10, 2022
- Data Supported juMPStart Trial Evaluating One-Time, Systemic Administration of HMI-203 in ERT-Treated Adults - - Details of HMI-203 Clinical Trial Design and Encouraging Preclinical Data... | February 10, 2022